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Abstract 
Background: The escalating rate of diabetes’ has prompted researchers around the world to explore for early mark-
ers. A deficit of functional β-cell mass plays a central role in the pathophysiology of type 2 diabetes. The REG (Regener-
ating) gene, encoding a 166 amino acid REG protein was discovered in rats and humans which is released in response 
to β-cells damage and play a role in their regeneration. The objective of this study was to characterize serum levels of 
REG Iα proteins in type 2 diabetic patients as indicator of β-cell apoptosis as well as regeneration.
Methods: Unrelated type 2 diabetic patients (n = 55) of different age groups and disease duration were recruited 
from the Medical OPD of PNS Shifa Hospital. Age and sex matched non diabetic controls (n = 20) without family his-
tory of diabetes were selected from the same setting. Demographical details were recorded on a structured question-
naire. Biochemical parameters like FBG, HbA1c, TC and TG levels were measured. Serum levels of REG Iα protein were 
determined by ELISA.
Results: Levels of REG Iα protein were found significantly raised in type 2 diabetic patients compared to controls 
(p < 001). Patients with short duration of the disease had higher levels of REG Iα as compared to patients with longer 
duration of the disease. Although the patients were on anti hyperglycemic agents, a positive correlation was found 
between REG Iα serum levels, FBG and HbA1c levels. Patients with higher BMI had higher levels of serum REG Iα levels. 
Serum TC, TG and Hb levels showed no correlation.
Conclusion: REG Iα may be used as a marker/predictor of type 2 diabetes especially in the early stages of the disease.
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Background
Pancreatic islet β-cells produce insulin which regulate 
body glucose metabolism, but their capacity for regen-
eration is limited, which plays a major role in the patho-
genesis of autoimmune type 1 and insulin resistant type 
2 diabetes [1]. An insufficiency in functional β-cell mass 
and their aptitude to secrete insulin is a characteristic 
feature of type 2 diabetes. Factors, other than renewal 
crisis, implicated in β-cell death in type 2 diabetes 
include glucolipotoxicity, amyloid deposits in pancreatic 
islet and high metabolic demand causing oxidative stress, 
endoplasmic reticulum stress as well as inflammatory 
signals such as cytokines production in the islet insulin 
producing cells have been associated with β-cell death in 
type 2 diabetes [2]. Future plan of action regarding pre-
vention as well as treatment of diabetes should include 
such strategies that lead to amplify functional β-cell mass 
in pancreas [3, 4]. A constant process of demise and res-
toration of β-cell mass is an ongoing process under physi-
ological conditions [5]. For normal functioning of islets 
β-cells a crucial balance between these two processes 
appears to be obligatory. To date no methods for assess-
ment of β-cell apoptosis in disease conditions in humans 
is available except for post mortem studies. These studies 
reported a deficit of up to sixty-five percent in pancreatic 
insulin producing cells in type 2 diabetes [6].
The novel REG (Regenerating) gene, encoding an 
approximately 17  kDa protein was discovered dur-
ing the screening of cDNA library derived from 
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regenerating and hyperplastic islet in rats and humans 
[7]. The Reg1 protein, normally a product of acinar cells 
of exocrine pancreas has mitogenic effect on β-cells of 
endocrine pancreas and has been shown to improve 
experimental diabetes in rats [8–10]. Reg1α protein 
causes replication of DNA in pancreatic β-cells and a 
receptor for Reg protein was identified that conveys a 
growth signal of Reg protein for regeneration of β-cells 
[11, 12]. In Reg knockout mice the size of islets were 
much smaller and they showed a lower proliferative 
capacity, while a delay in the onset of diabetes was 
observed in NOD mice carrying the Ins-Reg transgene 
[13], indicating a possible role of Reg family proteins in 
β-cell growth and regeneration. Reduction of Reg1 was 
linked with the pathogenesis of impaired glucose toler-
ance of diabetes [14], while treatment with Reg1 pro-
tein improved the islet β-cells ability to secrete insulin 
in rat models of diabetes, indicating its role in the 
pathogenesis of type 2 diabetes.
REG Iα is one of the five members of the human REG 
family proteins and is encoded by a gene positioned on 
chromosome 2p12 [4]. REG protein levels are signifi-
cantly increased in the islets from a diabetic patient, and 
antibodies against Reg protein which impede prolifera-
tion of β-cell are identified in the mouse models of diabe-
tes [15] and in some diabetic patients [16], suggesting its 
role in the pathogenesis of human diabetes. This evidence 
led to the present hypothesis that REG proteins expres-
sion is enhanced during type 2 diabetes in their effort to 
regenerate islet β-cells destroyed due to glucolipotoxicity 
and increased metabolic demand. Therefore, the objec-
tive of this project was to characterize serum levels of 
REG Iα proteins in patients of type 2 diabetes as mark-
ers of β-cell apoptosis and regeneration especially in the 
early stages of the disease.
Methods
Subjects
In this case control study unrelated patients (55) with dia-
betes were selected from the Medical OPD of PNS Shifa 
Hospital along with non-diabetic (20) controls. Prior to 
this the Ethical Committee of Army Medical College 
approved the study protocol. Blood samples (10 ml) were 
collected after an informed consent for serum analysis 
from each subject. Blood sample was collected in clot 
activator tubes and was allowed to clot for 30 min before 
centrifugation for 30 min at 2500×g, 2–8 °C. Serum was 
removed and stored in aliquots at −20 °C for ELISA and 
further analysis.
Serum REG Iα protein levels were measured in 55 
patients with type 2 diabetes with different age groups 
and disease duration and 20 normal sex/age matched 
controls. ADA criteria was used to assess the patients 
with type 2 diabetes [1]. Blood sample of each study sub-
ject was collected in the morning after an overnight fast. 
Height, weight, and blood pressure were measured. Bio-
chemical analysis of blood was done for FBG, HbA1c, TC 
and TG.
Quantification of serum REG Iα
The REG Iα protein was measured in serum of type 2 
diabetics using a human REG Iα BioAssay ELISA Kit 
(USBiological, life Science), which is a sandwich enzyme 
immunoassay for in  vitro quantitative measurement 
of REG Iα in human serum, plasma and other biologi-
cal fluids. Samples were diluted 1:500 with 0.01  M PBS 
as follows: 20 μl of sample were added to 180 μl of PBS 
(dilution 1:10); 10  μl of this dilution were pipetted into 
another 490  μl of PBS to prepare the 1:500 dilutions as 
per requirement. In the BioAssay Human REG Iα ELISA, 
100 μl of blank (PBS), standards and samples were added 
(in duplicates) in the wells of the microtiter strips coated 
with REG Iα specific antibody. The microtiter plate was 
incubated at 25  °C for 2 h. 100 µl of the Detection Rea-
gent A working solution (Biotin-conjugated antibody 
specific to REG Iα) was added to each well and incubated 
for 1 h at 37 °C. Wells were washed three times with 1× 
wash solution. 100 μl of the Detection Reagent B working 
solution [Avidin- conjugated with horseradish peroxidase 
(HRP)] was added to the wells and incubated for 30 min 
at 37  °C. Wells were washed five times with wash solu-
tion and incubated with 90 μl TMB substrate for 15 min 
at 37  °C. After adding Stop Solution, reading was done 
at wavelength of 450 nm with a Microplate reader/spec-
trophotometer. A standard curve was created by plotting 
mean absorbance for each standard verses REG Iα con-
centrations of the standards. The results are presented 
as REG Iα concentration (pg/ml) in the samples. The 
amount of REG Iα in the blood sample of the patients was 
calculated by multiplying the result obtained by dilution 
factor 500 (for example, 62.5 pg/ml × 500 = 31,250 pg/
ml). Readings were converted to ng/ml after multiplying 
by 0.001 (31,250 × 0.001 = 31.25). The antibodies used in 
this assay are specific for human REG Iα with no known 
cross reactivities to recombinant human REG proteins.
Statistical analysis
Descriptive and inferential statistics were calculated. To 
check the normality of the data Shapiro–Wilk test were 
applied. Mean  ±  SD OR median (inter quartile range) 
were calculated. The Mann–Whitney U test (for compar-
ison of two groups) and Kruskal–Wallis test (for compar-
ison of 3 or more than three groups) was used to compare 
quantitative variables. Spearman’s rank test was used for 
analysis of correlation between variables. Unless other-
wise indicated, p values of less than 0.05 were considered 
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significant. Statistical analysis was performed using SPSS 
statistical software, version 16.
Results
The clinical characteristics of the study subjects are 
shown in Table  1. Patients with type 2 diabetes had 
higher mean BMI, higher systolic blood pressure, higher 
FBG, HbA1c, fasting TC and TG levels as compared to 
the control subjects.
Serum REG Iα protein levels
Increased REG Iα protein levels were detected in type 
2 diabetes patients of different age groups and disease 
duration compared to age and sex matched controls with 
a p value of <0.001 (Fig. 1).
Metabolic and risk factors correlation
In type 2 diabetics, a negative correlation between dis-
ease duration and serum REG Iα protein levels was 
observed (p = 0.003, Spearman r = −0.39) (Figs. 1b, 2a). 
Although the protein levels decreased with increase in 
the duration of the disease they remained significantly 
higher than the controls. Type 2 diabetes patients were 
divided into four groups according to the duration of 
disease. Group 1 (n = 13) patients with duration of dis-
ease less than 2  years. Group 2 (n  =  14) patients with 
duration of disease 2–5 years. Group 3 (n = 14) patients 
with duration of disease 5–10  years. Group 4 (n  =  14) 
patients with duration of disease more than 10 years. Sig-
nificant difference was found between the four groups 
with p < 0.05. Between any two groups p value was cal-
culated to be significant or non significant (Group 1 
and 2 p = 0.23), (Group 1 and 3 p < 0.05), (Group 1 and 
4 p  <  0.05), (Group 2 and 3 p =  0.31), (Group 2 and 4 
p = 0.15) and (Group 3 and 4 p = 0.63). Serum REG Iα 
levels also showed a decline in their levels with increasing 
age of patient (p = 0.019) (Fig. 2b).
Although the patients were on anti hyperglyce-
mic agents, significant positive correlation was found 
between REG Iα serum levels, FBG and HbA1c levels in 
type 2 diabetics (Fig.  2c, d). Serum cholesterol, serum 
triglycerides and hemoglobin levels in type 2 diabetics 
showed no correlation with circulatory REG Iα levels. 
Risk factors like smoking and family history of diabetes 
also did not show any correlation with the REG Iα serum 
levels in type 2 diabetics. Smokers have slightly higher 
levels of serum REG Iα compared to the non smokers.
Systolic blood pressure (p =  0.06) and diastolic blood 
pressure (p =  0.16) were found directly proportional to 
increase in age, duration of the disease and decrease in 
REG Iα protein levels.
Patients with increased body weight had higher levels 
of REG Iα protein with a p value of 0.001 and Spearman 
r = 0.42 (Fig. 3).
Discussion
Worldwide there is scarcity of studies regarding role 
of REG Iα in type 2 diabetes in humans. However, in 
the developing world where diabetes is becoming a 
leading cause of death, there are no exploratory stud-
ies. Pakistan now ranks seventh in terms of diabetes 
having 6.9 million cases of diabetes in 2014 according 
to International Diabetes Federation. A wide range of 
evidence suggests that a deficit of functional β-cell 
mass plays a key role in the pathophysiology of dia-
betes [17, 18] and expression of Reg genes following 
β-cell damage play a role in their regeneration and/or 
neogenesis [12].
In this study serum levels of REG Iα protein were found 
significantly increased in type 2 diabetes patient com-
pared to control subjects. The elevated levels of REG Iα 
in the serum was observed in newly diagnosed patients 
with type 2 diabetes, and to a lesser degree, in patients 
with longer duration of the disease. Interestingly, type 
2 diabetics with long term disease displayed relatively 
decreased REG Iα levels and a negative correlation was 
observed between serum REG Iα levels and disease dura-
tion. A negative correlation was also observed between 
serum REG Iα levels and age of the type 2 diabetes 
patients.
Table 1 Clinical characteristics of the study subjects
Data are given as mean ± standard deviation for normally distributed variables, 
and otherwise as medians (inter quartile range). P values of BMI was adjusted 
for age and sex. P values of blood pressure, FBG, HbA1c, and lipid profiles were 
adjusted for age, sex, and BMI
BMI body mass index
P values for differences between control group and type 2 diabetes patients.  
(* significant, ** highly significant)
Parameters Control (n = 20) Type 2 (n = 55) p value
Sex, M/F 12/8 40/15 –
Age (years) 51 ± 3 55 ± 9 –
Age at diagnosis of  
disease (years)
– 48.6 ± 8.5 –
Duration of diabetes 
(years)
– 7.0 ± 5.8 –
BMI (kg/m2) 23.98 ± 4.01 25.5 ± 3.9 <0.032*
Systolic blood pressure 
(mmHg)
120 (110–120) 130 (120–140) <0.001**
Diastolic blood pressure 
(mmHg)
80 (70–80) 80 (80–90) <0.001**
FBG (mmol/L) 3.7 (3.5–4.4) 7.8 (6.1–9.5) <0.001**
HbA1c (%) 5.5 (5.4–5.6) 7.8 (6.9–9.0) <0.001**
TC (mmol/L) 3.7 (3.2–4.7) 5.1 (4.5–5.6) <0.001**
TG (mmol/L) 1.15 (0.9–1.3) 1.7 (1.2–2.3) <0.041*
Hb (mg/dL) 13.2 (12.6–14.2) 12.0 (11.6–12.8) <0.054
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This study on REG Iα is the first of its kind in type 2 
diabetes patients of Pakistani background. Increased cir-
culatory levels of REG Iα in type 1 and type 2 diabetes 
patient was reported previously in a large scale study 
conducted in Caucasian population [19]. REG Iα serum 
levels were also found elevated from third decade of life 
onwards in patients of maturity onset diabetes of the 
young (MODY) [20]. Our study also validate the previous 
widespread work done on experimental models of diabe-
tes and pancreatic β-cell regeneration [13]. Reg1 expres-
sion was also demonstrated to be up regulated at very 
early stage in high fat diet induced mice models of obe-
sity and type 2 diabetes [21]. This rise is the response of 
pancreas to hyperglycemia by enhancing the proliferation 
of pancreatic β-cells and their ability to secrete insulin.
It has been observed that damage to β-cells, due to 
their infiltration by immune cells, is responsible for up 
regulation of Reg1 genes expression [4]. The pathologi-
cal role of inflammatory mechanism in obesity and type 
2 diabetes has been reported by many studies in the last 
decade [22, 23]. In islets of spontaneous rat models of 
type 2 diabetes there was increased expression of Reg1 
and Reg3 in association with peri-islet macrophage infil-
tration and release of various cytokines/chemokines, 
particularly IL-6. [24]. Addition of IL-6 and Dx together 
in human 1.1B4 β-cell lines induced REG Iα and REG Iβ 
expression [25]. An IL-6 response element has been iden-
tified in the promoter region of Reg1 gene and the local 
IL-6 levels plays a crucial role in influencing Reg gene 
expression [26]. A recent study has shown that apoptotic 
β-cells shed microparticles that stimulate  expression of 
Reg1α in neighboring cells, to facilitate β-cell regenera-
tion thereby forming a link between β-cell apoptosis and 
β-cell regeneration. Moreover, the same study also dem-
onstrated that extracellular high glucose concentration 
potentiates Reg gene expression [27]. Increased serum 
levels of REG Iα protein in patients with type 2 diabetes 
in present study is in agreement with the hypothesis that 
the deficit in β-cell mass due to increase in β-cell damage 
secondary to high metabolic demand and inflammation 
leads to upregulation of REG Iα in regenerating β-cells 
and acinar cells.
On the contrary, increased REG Iα levels have also 
been reported in conditions like Celiac disease [28], ven-
tilator associated pneumonia [29] sepsis [30] and also in 
other conditions of inflammation and infections, how-
ever, the main source of REG Iα remains to be pancreas. 
Moreover, at the time of sampling all such conditions 
other than diabetes which lead to raised serum Reg Iα 
were excluded.
In the present study type 2 diabetics with long term 
disease demonstrated relatively decreased levels of REG 
Iα and a negative association was found between serum 
REG Iα levels and duration of disease. A negative cor-
relation between circulatory REG Iα protein and dura-
tion of disease has been previously reported in case of 
type 1 diabetics [19]. However, no correlation between 
age or disease onset and REG Iα levels was found in 
Fig. 1 Human REG Iα ELISA assay (USBiological, Life Sciences). Quantitative measurement of human REG Iα protein in serum. a Increased levels of 
REG Iα protein were observed in type 2 diabetes patients compared to controls (p < 0.001). b Serum REG Iα levels between different groups of type 
2 diabetes patients. Significant relationship was found between the groups p < 0.05
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type 1 diabetics while raised REG Iα levels were found in 
patients with MODY diagnosed in the third decade of life 
onwards as compared to those diagnosed earlier in life 
[20]. These patients had much less mean age compared 
to type 2 diabetics in our study. A recent pilot study 
conducted by Yang and colleagues reported significant 
upregulation of REG I gene in type 2 diabetes in accord-
ance with our study, however, they related this increase 
with the clinical stages of the disease and its associated 
complication [31]. It has been reported that aging is asso-
ciated with a decline in β-cells proliferation capacity [32]. 
A decline in the Reg1 expression has been observed in 
mice models during the normal aging process and age-
related islet dysfunction [33]. In the process of aging and 
pancreatitis-associated diabetes the decrease in acinar 
cells, the main source of Reg1 has been demonstrated 
[14]. In type 2 diabetes with the increase in the duration 
of disease a reduction in functional β-cell mass occurs 
Fig. 2 Correlation between clinical characteristics and serum REG Iα protein in type 2 diabetes patients. a Correlation between disease duration 
and serum REG Iα protein. b Correlation between age of patient and serum REG Iα protein in type 2 diabetes patients. c Correlation between FBG 
and serum REG Iα protein in type 2 diabetes patients. d Correlation between HbA1c and serum REG Iα protein in type 2 diabetes patients
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[34], thus one-third of patients with long disease dura-
tion were found to be on insulin therapy. High intracel-
lular levels of Reg I lead to inhibition of β-cell growth and 
possible induction of their apoptosis or differentiation 
into other cell types [35]. Thus, the relative decrease in 
REG Iα levels with age and duration of the disease may 
be due to substantial damage to β-cells that occur in late 
stages of type 2 diabetes, decrease regeneration capac-
ity of β-cells with age and age related decrease in acinar 
cells, the main source of REG I.
It was however interesting to find that the type 2 dia-
betes patients with longer duration of the disease and 
with known diabetic complications were found to have 
much higher REG Iα levels (data not shown). The exact 
source of increase serum REG Iα levels is unknown. 
REG I expression has been addressed as a defense 
mechanism to the inflammatory response. The other 
organs damaged/inflamed in these cases may possi-
bly have contributed. Despite the fact that the patients 
were on anti-hypertensive medication, an increase in 
the systolic and diastolic blood pressure were observed. 
In patients with uncontrolled diabetes increased blood 
pressure is an important risk factor for death and dis-
ability [36]. Increased levels of Reg Iα in response to 
β-cell damage has been associated with β-cell regenera-
tion and increase in their insulin secretory capacity [8], 
leading to better control of diabetes and its associated 
risk factors. However, serum cholesterol, triglycerides 
and hemoglobin levels in type 2 diabetics in this study 
showed no correlation with circulatory REG Iα levels. 
Interestingly, a positive though insignificant correlation 
between REG Iα and smoking was observed. This is 
possibly due to nicotine in cigarettes, which is associ-
ated with apoptosis of β-cells [37] releasing REG Iα.
A significant correlation was found between serum 
REG Iα, FBG and HbA1c levels in type 2 diabetics; higher 
REG Iα levels had higher FBG and HbA1c levels. Studies 
have shown that high glucose concentration potentiates 
Reg gene expression [21, 27]. A recent study conducted 
by Yang also reported a positive correlation between REG 
Iα and HbA1c levels in type 2 diabetics [31], while no 
correlation was found between REG Iα and HbA1c levels 
in type1 diabetics and in patients with MODY [19, 20]. 
One of the reasons behind reduced glycemic control in 
the early stages of the disease was the poor compliance 
of the patient due to lack of knowledge. Patients with 
increase BMI had higher serum levels of the Reg Iα pro-
tein showing a positive correlation. Relative β-cell mass 
was demonstrated to be increased in obese versus lean, 
non diabetic subjects [2, 38]. Obesity associated insu-
lin resistance and hyperglycemia may be responsible for 
increase in the serum REG Iα levels in this study.
Conclusion
In this study REG Iα is demonstrated to be significantly 
upregulated in serum of type 2 diabetes patients, espe-
cially in patients of short duration of the disease and may 
be used as a marker of β-cell damage in type 2 diabetes in 
the early stages of the disease. Large scale studies in dia-
betic patients are required with different duration of the 
disease to further verify the significance of REG Iα pro-
tein as an indicator of β-cell regeneration and/or β-cell 
apoptosis.
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